OPKO Health to Announce Fourth Quarter and Year End 2017 Financial Results on March 1, 2018 Feb 26, 2018
OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy Nov 27, 2017
OPKO Health Submits Premarket Approval Application with FDA for a Point-of-Care PSA Test with the Claros® 1 Platform Nov 7, 2017
OPKO Health Licensee TESARO Announces FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated with Chemotherapy Oct 26, 2017
OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan Oct 12, 2017
OPKO’s BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care Sep 19, 2017
